Inhibition of renin activity slows down the progression of HIV-associated nephropathy

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 5, 2012, Pages

  Kumar, Dileep ^a   Plagov, Andrei ^a   Yadav, Iti ^a   Torri, Deepti D ^a   Sayeneni, Swapna ^a   Sagar, Ankita ^a   Rai, Partab ^a   Adabala, Madhuri ^a   Lederman, Rivka ^a   Chandel, Nirupama ^a   Ding, Guohua ^a   Malhotra, Ashwani ^a   Singhal, Pravin C ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Glomerulosclerosis; Human immunodeficiency virus; Microcysts

Indexed keywords

ALISKIREN; ANGIOTENSIN I; DOXYCYCLINE; DRINKING WATER; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOCAL GLOMERULOSCLEROSIS; HIV ASSOCIATED NEPHROPATHY; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUBULE DISORDER; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; UREA BLOOD LEVEL;

EID: 84865792702     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00643.2011     Document Type: Article

References (37)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13: 9-20, 2007.
2. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109: 2492-2499, 2004.
3. Brown JJ, Lever AF, Davies DL, Robertson JI. Renin and angiotensin. A survey of some aspects. Postgrad Med J 42: 153-176, 1966.
4. Bruggeman LA, Nelson PJ. Controversies in the pathogenesis of HIVassociated renal diseases. Nat Rev Nephrol 5: 574-581, 2009.
5. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20: 893-900, 2009.
6. Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8: 1140-1146, 1997.
7. Campbell RC, Ruggeneti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 13: 190-195, 2002.
8. Danser AJ. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res 33: 4-10, 2010.
9. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, Kopp JB. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 322: 69-81, 2004.
10. Ellmers LJ, Scott NJ, Medicherla S, Pilbrow AP, Bridgman PG, Yandle TG, Richards AM, Protter AA, Cameron VA. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 149: 5828-5834, 2008.
11. Favre L, Vallotton MB, Muller AF. Relationship between plasma concentrations of angiotensin I, angiotensin II and plasma renin activity during cardio-pulmonary bypass in man. Eur J Clin Invest 4: 135-140, 1974.
12. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4: 361-368, 2009.
13. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensinaldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16: 120-126, 2005.
14. Haefliger JA, Krattinger N, Martin D, Pedrazzini T, Capponi A, Döring B, Plum A, Charollais A, Willecke K, Meda P. Connexin43-dependent mechanism modulates renin secretion and hypertension. J Clin Invest 116: 405-413. 2006.
15. Hiramatsu N, Hiromura K, Shigehara T, Kuroiwa T, Ideura H, Sakurai N, Takeuchi S, Tomioka M, Ikeuchi H, Kaneko Y, Ueki K, Kopp JB, Nojima Y. Angiotensin II type 1 receptor blockade inhibits the development and progression. J Am Soc Nephrol 18: 515-27, 2007.
16. Hollenberg NK. Direct renin inhibition and the kidney. Nat Rev Nephrol 6: 49-55, 2010.
17. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738-1747, 2003.
18. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006.
19. Ideura H, Hiromura K, Hiramatsu N, Shigehara T, Takeuchi S, Tomioka M, Sakairi T, Yamashita S, Maeshima A, Kaneko Y, Kuroiwa T, Kopp JB, Nojima Y. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol 293: F1214-F1221, 2007.
20. Klotman PE, Rappaport J, Ray P, Kopp JB, Franks R, Bruggeman LA, Notkins AL. Transgenic models of HIV-1. AIDS 9: 313-324, 1995.
21. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
22. Kumar D, Salhan D, Magoon S, Torri DD, Sayeneni S, Sagar A, Bandhlish A, Malhotra A, Chander PN, Singhal PC. Adverse host factors exacerbate occult HIV-associated nephropathy. Am J Pathol 179: 1681-1692, 2011.
23. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002.
24. Lu TC, He JC, Klotman P. Animal models of HIV-associated nephropathy. Curr Opin Nephrol Hypertens 15: 233-237, 2006.
25. Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 20: 646-655, 2007.
26. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001.
27. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
28. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
29. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 16: 3027-3037, 2005.
30. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression, and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006.
31. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simõese Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 4: 787-803, 2008.
32. Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21: 53-57, 2000.
33. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 3: 1511-1525, 2008.
34. Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Takeuchi S, Tomioka M, Shigehara T, Maeshima A, Kaneko Y, Hiromura K, Kopp JB, Nojima Y. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol Dial Transplant 24: 2378-2383, 2009.
35. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 37: 1811-1819, 1991.
36. Todorov V, Muller M, Schweda F, Kurtz A. Tumor necrosis factoralpha inhibits renin gene expression. Am J Physiol Regul Integr Comp Physiol 283: R1046-R1051, 2002.
37. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.